305 related articles for article (PubMed ID: 22096244)
1. P-selectin glycoprotein ligand regulates the interaction of multiple myeloma cells with the bone marrow microenvironment.
Azab AK; Quang P; Azab F; Pitsillides C; Thompson B; Chonghaile T; Patton JT; Maiso P; Monrose V; Sacco A; Ngo HT; Flores LM; Lin CP; Magnani JL; Kung AL; Letai A; Carrasco R; Roccaro AM; Ghobrial IM
Blood; 2012 Feb; 119(6):1468-78. PubMed ID: 22096244
[TBL] [Abstract][Full Text] [Related]
2. PSGL-1/selectin and ICAM-1/CD18 interactions are involved in macrophage-induced drug resistance in myeloma.
Zheng Y; Yang J; Qian J; Qiu P; Hanabuchi S; Lu Y; Wang Z; Liu Z; Li H; He J; Lin P; Weber D; Davis RE; Kwak L; Cai Z; Yi Q
Leukemia; 2013 Mar; 27(3):702-10. PubMed ID: 22996336
[TBL] [Abstract][Full Text] [Related]
3. In vivo adhesion of malignant B cells to bone marrow microvasculature is regulated by α4β1 cytoplasmic-binding proteins.
Martínez-Moreno M; Leiva M; Aguilera-Montilla N; Sevilla-Movilla S; Isern de Val S; Arellano-Sánchez N; Gutiérrez NC; Maldonado R; Martínez-López J; Buño I; García-Marco JA; Sánchez-Mateos P; Hidalgo A; García-Pardo A; Teixidó J
Leukemia; 2016 Apr; 30(4):861-72. PubMed ID: 26658839
[TBL] [Abstract][Full Text] [Related]
4. Tumor microenvironment-targeted nanoparticles loaded with bortezomib and ROCK inhibitor improve efficacy in multiple myeloma.
Federico C; Alhallak K; Sun J; Duncan K; Azab F; Sudlow GP; de la Puente P; Muz B; Kapoor V; Zhang L; Yuan F; Markovic M; Kotsybar J; Wasden K; Guenthner N; Gurley S; King J; Kohnen D; Salama NN; Thotala D; Hallahan DE; Vij R; DiPersio JF; Achilefu S; Azab AK
Nat Commun; 2020 Nov; 11(1):6037. PubMed ID: 33247158
[TBL] [Abstract][Full Text] [Related]
5. Functional selectin ligands mediating human CD34(+) cell interactions with bone marrow endothelium are enhanced postnatally.
Hidalgo A; Weiss LA; Frenette PS
J Clin Invest; 2002 Aug; 110(4):559-69. PubMed ID: 12189250
[TBL] [Abstract][Full Text] [Related]
6. CXCR4 inhibitor AMD3100 disrupts the interaction of multiple myeloma cells with the bone marrow microenvironment and enhances their sensitivity to therapy.
Azab AK; Runnels JM; Pitsillides C; Moreau AS; Azab F; Leleu X; Jia X; Wright R; Ospina B; Carlson AL; Alt C; Burwick N; Roccaro AM; Ngo HT; Farag M; Melhem MR; Sacco A; Munshi NC; Hideshima T; Rollins BJ; Anderson KC; Kung AL; Lin CP; Ghobrial IM
Blood; 2009 Apr; 113(18):4341-51. PubMed ID: 19139079
[TBL] [Abstract][Full Text] [Related]
7. Annexin II interactions with the annexin II receptor enhance multiple myeloma cell adhesion and growth in the bone marrow microenvironment.
D'Souza S; Kurihara N; Shiozawa Y; Joseph J; Taichman R; Galson DL; Roodman GD
Blood; 2012 Feb; 119(8):1888-96. PubMed ID: 22223826
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of P-Selectin and PSGL-1 Using Humanized Monoclonal Antibodies Increases the Sensitivity of Multiple Myeloma Cells to Bortezomib.
Muz B; Azab F; de la Puente P; Rollins S; Alvarez R; Kawar Z; Azab AK
Biomed Res Int; 2015; 2015():417586. PubMed ID: 26539491
[TBL] [Abstract][Full Text] [Related]
9. Sphingosine-1-phosphate activates chemokine-promoted myeloma cell adhesion and migration involving α4β1 integrin function.
García-Bernal D; Redondo-Muñoz J; Dios-Esponera A; Chèvre R; Bailón E; Garayoa M; Arellano-Sánchez N; Gutierrez NC; Hidalgo A; García-Pardo A; Teixidó J
J Pathol; 2013 Jan; 229(1):36-48. PubMed ID: 22711564
[TBL] [Abstract][Full Text] [Related]
10. Expression of XBP1s in bone marrow stromal cells is critical for myeloma cell growth and osteoclast formation.
Xu G; Liu K; Anderson J; Patrene K; Lentzsch S; Roodman GD; Ouyang H
Blood; 2012 May; 119(18):4205-14. PubMed ID: 22427205
[TBL] [Abstract][Full Text] [Related]
11. N-cadherin-mediated interaction with multiple myeloma cells inhibits osteoblast differentiation.
Groen RW; de Rooij MF; Kocemba KA; Reijmers RM; de Haan-Kramer A; Overdijk MB; Aalders L; Rozemuller H; Martens AC; Bergsagel PL; Kersten MJ; Pals ST; Spaargaren M
Haematologica; 2011 Nov; 96(11):1653-61. PubMed ID: 21828122
[TBL] [Abstract][Full Text] [Related]
12. Overexpression of P-selectin glycoprotein ligand-1 enhances adhesive properties of endothelial progenitor cells through Syk activation.
Cao L; Li L; Yang H; Yin H
Acta Biochim Biophys Sin (Shanghai); 2010 Aug; 42(8):507-14. PubMed ID: 20705591
[TBL] [Abstract][Full Text] [Related]
13. The selective adhesion molecule inhibitor Natalizumab decreases multiple myeloma cell growth in the bone marrow microenvironment: therapeutic implications.
Podar K; Zimmerhackl A; Fulciniti M; Tonon G; Hainz U; Tai YT; Vallet S; Halama N; Jäger D; Olson DL; Sattler M; Chauhan D; Anderson KC
Br J Haematol; 2011 Nov; 155(4):438-48. PubMed ID: 21923653
[TBL] [Abstract][Full Text] [Related]
14. CS1 promotes multiple myeloma cell adhesion, clonogenic growth, and tumorigenicity via c-maf-mediated interactions with bone marrow stromal cells.
Tai YT; Soydan E; Song W; Fulciniti M; Kim K; Hong F; Li XF; Burger P; Rumizen MJ; Nahar S; Podar K; Hideshima T; Munshi NC; Tonon G; Carrasco RD; Afar DE; Anderson KC
Blood; 2009 Apr; 113(18):4309-18. PubMed ID: 19196658
[TBL] [Abstract][Full Text] [Related]
15. Eph-B2/ephrin-B2 interaction plays a major role in the adhesion and proliferation of Waldenstrom's macroglobulinemia.
Azab F; Azab AK; Maiso P; Calimeri T; Flores L; Liu Y; Quang P; Roccaro AM; Sacco A; Ngo HT; Zhang Y; Morgan BL; Carrasco RD; Ghobrial IM
Clin Cancer Res; 2012 Jan; 18(1):91-104. PubMed ID: 22010211
[TBL] [Abstract][Full Text] [Related]
16. Bruton tyrosine kinase inhibition is a novel therapeutic strategy targeting tumor in the bone marrow microenvironment in multiple myeloma.
Tai YT; Chang BY; Kong SY; Fulciniti M; Yang G; Calle Y; Hu Y; Lin J; Zhao JJ; Cagnetta A; Cea M; Sellitto MA; Zhong MY; Wang Q; Acharya C; Carrasco DR; Buggy JJ; Elias L; Treon SP; Matsui W; Richardson P; Munshi NC; Anderson KC
Blood; 2012 Aug; 120(9):1877-87. PubMed ID: 22689860
[TBL] [Abstract][Full Text] [Related]
17. HIF-1α inhibition blocks the cross talk between multiple myeloma plasma cells and tumor microenvironment.
Borsi E; Perrone G; Terragna C; Martello M; Zamagni E; Tacchetti P; Pantani L; Brioli A; Dico AF; Zannetti BA; Rocchi S; Cavo M
Exp Cell Res; 2014 Nov; 328(2):444-55. PubMed ID: 25257607
[TBL] [Abstract][Full Text] [Related]
18. PSGL-1 decorated with sialyl Lewis
O'Dwyer M; Kirkham-McCarthy L; Cerreto M; Foà R; Natoni A
Sci Rep; 2024 Jan; 14(1):1756. PubMed ID: 38243063
[TBL] [Abstract][Full Text] [Related]
19. E-selectin ligands recognised by HECA452 induce drug resistance in myeloma, which is overcome by the E-selectin antagonist, GMI-1271.
Natoni A; Smith TAG; Keane N; McEllistrim C; Connolly C; Jha A; Andrulis M; Ellert E; Raab MS; Glavey SV; Kirkham-McCarthy L; Kumar SK; Locatelli-Hoops SC; Oliva I; Fogler WE; Magnani JL; O'Dwyer ME
Leukemia; 2017 Dec; 31(12):2642-2651. PubMed ID: 28439107
[TBL] [Abstract][Full Text] [Related]
20. Generation of soluble P- and E-selectins in vivo is dependent on expression of P-selectin glycoprotein ligand-1.
Bodary PF; Homeister JW; Vargas FB; Wickenheiser KJ; Cudney SS; Bahrou KL; Ohman M; Rabbani AB; Eitzman DT
J Thromb Haemost; 2007 Mar; 5(3):599-603. PubMed ID: 17229053
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
